Revance Therapeutics, Inc. (RVNC) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Revance Therapeutics, Inc. (RVNC) Bundle
Simplify Revance Therapeutics, Inc. (RVNC) valuation with this customizable DCF Calculator! Featuring real Revance Therapeutics, Inc. (RVNC) financials and adjustable forecast inputs, you can test scenarios and uncover Revance Therapeutics, Inc. (RVNC) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .4 | 15.3 | 77.8 | 132.6 | 234.0 | 437.0 | 816.1 | 1,524.0 | 2,845.8 | 5,314.1 |
| Revenue Growth, % | 0 | 3610.65 | 407.65 | 70.4 | 76.55 | 86.74 | 86.74 | 86.74 | 86.74 | 86.74 |
| EBITDA | -156.5 | -259.3 | -255.2 | -305.5 | -290.6 | -437.0 | -816.1 | -1,524.0 | -2,845.8 | -5,314.1 |
| EBITDA, % | -37898.31 | -1692.07 | -328.01 | -230.47 | -124.18 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.9 | 10.3 | 19.9 | 33.7 | 13.7 | 195.5 | 365.1 | 681.8 | 1,273.2 | 2,377.6 |
| Depreciation, % | 704.36 | 66.89 | 25.52 | 25.45 | 5.85 | 44.74 | 44.74 | 44.74 | 44.74 | 44.74 |
| EBIT | -159.4 | -269.6 | -275.0 | -339.2 | -304.3 | -437.0 | -816.1 | -1,524.0 | -2,845.8 | -5,314.1 |
| EBIT, % | -38602.66 | -1758.96 | -353.53 | -255.91 | -130.03 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 290.1 | 436.5 | 225.1 | 340.7 | 253.9 | 437.0 | 816.1 | 1,524.0 | 2,845.8 | 5,314.1 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 1.8 | 3.3 | 11.3 | 27.7 | 32.0 | 59.8 | 111.6 | 208.4 | 389.2 |
| Account Receivables, % | 0 | 11.93 | 4.3 | 8.55 | 11.83 | 7.32 | 7.32 | 7.32 | 7.32 | 7.32 |
| Inventories | .0 | 5.9 | 10.2 | 18.3 | 45.6 | 74.0 | 138.2 | 258.1 | 482.0 | 900.1 |
| Inventories, % | 0 | 38.34 | 13.05 | 13.82 | 19.47 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 |
| Accounts Payable | 8.0 | 12.7 | 10.6 | 4.5 | 13.8 | 179.7 | 335.5 | 626.5 | 1,169.9 | 2,184.6 |
| Accounts Payable, % | 1939.47 | 82.59 | 13.63 | 3.43 | 5.9 | 41.11 | 41.11 | 41.11 | 41.11 | 41.11 |
| Capital Expenditure | -3.2 | -4.2 | -18.1 | -23.0 | -6.9 | -149.5 | -279.2 | -521.3 | -973.5 | -1,817.9 |
| Capital Expenditure, % | -784.02 | -27.51 | -23.23 | -17.36 | -2.94 | -34.21 | -34.21 | -34.21 | -34.21 | -34.21 |
| Tax Rate, % | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 | -0.09268241 |
| EBITAT | -156.2 | -267.1 | -280.4 | -339.9 | -304.6 | -434.5 | -811.3 | -1,515.0 | -2,829.1 | -5,282.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -148.5 | -264.1 | -286.5 | -351.4 | -332.1 | -255.4 | -661.5 | -1,235.2 | -2,306.7 | -4,307.3 |
| WACC, % | 5.97 | 6 | 6.03 | 6.03 | 6.03 | 6.01 | 6.01 | 6.01 | 6.01 | 6.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6,909.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4,393 | |||||||||
| Terminal Value | -109,498 | |||||||||
| Present Terminal Value | -81,776 | |||||||||
| Enterprise Value | -88,685 | |||||||||
| Net Debt | 341 | |||||||||
| Equity Value | -89,026 | |||||||||
| Diluted Shares Outstanding, MM | 85 | |||||||||
| Equity Value Per Share | -1,052.32 |
What You Will Get
- Real RVNC Financial Data: Pre-filled with Revance Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Revance Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Revance Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Monitor Revance’s intrinsic value recalculating instantly.
- Intuitive Visual Outputs: Dashboard graphs illustrate valuation results and essential metrics.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Access the ready-to-use Excel file with Revance Therapeutics, Inc.'s (RVNC) financial data.
- Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations update in real-time.
- Test Scenarios: Create multiple projections and compare outcomes instantly.
- Make Decisions: Use the valuation results to guide your investment strategy.
Why Choose This Calculator for Revance Therapeutics, Inc. (RVNC)?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and industry consultants.
- Accurate Financials: Revance's historical and projected financial data preloaded for precision.
- Forecast Simulation: Effortlessly test various scenarios and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Comprehensive step-by-step instructions to assist you throughout the process.
Who Should Use Revance Therapeutics, Inc. (RVNC)?
- Investors: Gain insights into innovative therapeutics to make informed investment choices.
- Healthcare Analysts: Streamline your research with comprehensive data on Revance's pipeline and market potential.
- Consultants: Tailor presentations or reports quickly with up-to-date information on Revance's offerings.
- Pharmaceutical Enthusiasts: Enhance your knowledge of cutting-edge treatments and their impacts on patient care.
- Educators and Students: Utilize it as a valuable resource for studying biopharmaceutical advancements and market strategies.
What the Template Contains
- Pre-Filled DCF Model: Revance Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Revance Therapeutics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.